
Tezspire approved in EU for ‘challenging’ rhinosinusitis
AstraZeneca and Amgen’s Tezspire (tezepelumab) has been approved in the European Union for chronic rhinosinusitis with nasal polyps. Tezspire has been approved as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately responded to standard… Read More















